28th October 2010 -- David Burns, CEO of Glasgow-based Renishaw Diagnostics Ltd, has been appointed to the Life Sciences Advisory Board (LiSAB) for Scotland.
LiSAB is a joint industry, enterprise and government strategy team which develops and drives the overall life sciences strategy in Scotland. It consists of representatives from across the spectrum of the life sciences community.
David has more than twenty years of International executive experience as a sales, marketing and business development professional. Prior to joining Renishaw Diagnostics, David held senior leadership positions in the USA and Canada with Cyntellect Inc. as VP Sales and Marketing and COO, GE Healthcare Life Sciences (formerly Amersham Biosciences) where he filled the roles of Head of Strategic Growth and VP Commercial Alliances. Prior to that, he was CEO of Imaging Research Inc. in Ontario, Canada which was acquired by Amersham in 2003. David joined IRI and the Amersham group from a role as Vice-President Business Development and Marketing at Packard-BioSignal Inc. in Montreal, Quebec.
David’s experience also includes executive business development and marketing positions with Packard Bioscience in the USA and Netherlands, and in scientific sales with Pharmacia/LKB in the UK.
Commenting on his appointment David said, “I am delighted to be appointed as a member of LiSAB where I will have the opportunity to work with life science leaders from across the country and provide international experience and input from the molecular diagnostics sector into future strategic goals for Scottish life sciences”.
About Renishaw Diagnostics Ltd
Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases. The Company is based in Glasgow, Scotland, and further information is available at www.renishawdiagnostics.com.